{{Drugbox
| IUPAC_name = (3''R'')-3-(Prop-2-yn-1-yloxy)-1-azabicyclo[2.2.2]octane
| image = Talsaclidine.svg
| alt = Skeletal formula of talsaclidine
| width = 175
| image2 = Talsaclidine 3D ball.png
| alt2 = Ball-and-stick model of the talsaclidine molecule

<!--Clinical data-->
| tradename =
| pregnancy_category =
| legal_status =
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability = 70%
| protein_bound = 7%
| metabolism =
| elimination_half-life =
| excretion = [[Renal]] (86%)

<!--Identifiers-->
| CAS_number = 147025-53-4
| ATC_prefix = None
| ATC_suffix =
| PubChem = 71792
| ChemSpiderID = 64819
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 1O8VSL798T

<!--Chemical data-->
| C=10 | H=15 | N=1 | O=1 
| molecular_weight = 165.23 g/mol
| smiles = O([C@@H]2C1CCN(CC1)C2)CC#C
}}

'''Talsaclidine''' ('''WAL-2014''') is a non-[[binding selectivity|selective]] [[muscarinic acetylcholine receptor]] [[agonist]] which acts as a [[full agonist]] at the [[muscarinic acetylcholine receptor M1|M<sub>1</sub> subtype]], and as a [[partial agonist]] at the [[muscarinic acetylcholine receptor M2|M<sub>2</sub>]] and [[muscarinic acetylcholine receptor M3|M<sub>3</sub> subtype]]s.<ref name="pmid8441328">{{cite journal  |vauthors=Ensinger HA, Doods HN, Immel-Sehr AR, etal | title = WAL 2014--a muscarinic agonist with preferential neuron-stimulating properties | journal = Life Sciences | volume = 52 | issue = 5-6 | pages = 473–80 | year = 1993 | pmid = 8441328 | doi = 10.1016/0024-3205(93)90304-L| url = }}</ref><ref name="pmid9121364">{{cite journal |vauthors=Walland A, Burkard S, Hammer R, Tröger W | title = In vivo consequences of M1-receptor activation by talsaclidine | journal = Life Sciences | volume = 60 | issue = 13-14 | pages = 977–84 | year = 1997 | pmid = 9121364 | doi = 10.1016/S0024-3205(97)00037-4| url = }}</ref><ref name="pmid11392631">{{cite journal  |vauthors=Wienrich M, Meier D, Ensinger HA, etal | title = Pharmacodynamic profile of the M1 agonist talsaclidine in animals and man | journal = Life Sciences | volume = 68 | issue = 22-23 | pages = 2593–600 |date=April 2001 | pmid = 11392631 | doi = 10.1016/S0024-3205(01)01057-8| url = }}</ref> It was under development for the treatment of [[Alzheimer's disease]] but showed only modest or poor [[efficacy]] in [[rhesus monkey]]s and [[human]]s, respectively,<ref name="pmid11392631"/><ref name="pmid12122487">{{cite journal |vauthors=Terry AV, Buccafusco JJ, Borsini F, Leusch A | title = Memory-related task performance by aged rhesus monkeys administered the muscarinic M(1)-preferring agonist, talsaclidine | journal = Psychopharmacology | volume = 162 | issue = 3 | pages = 292–300 |date=July 2002 | pmid = 12122487 | doi = 10.1007/s00213-002-1105-3 | url = }}</ref> perhaps due to an array of dose-limiting [[side effect]]s including increased [[heart rate]] and [[blood pressure]], increased [[salivation]], [[urinary frequency]] and [[dysuria|burning upon urination]], increased [[lacrimation]] and [[rhinorrhea|nasal secretion]], abnormal [[accommodation (eye)|accommodation]], [[heartburn]], [[upset stomach]] as well as [[cramp]]s, [[nausea]], [[vomiting]] and [[diarrhea]], excessive [[sweating]] and [[palpitation]]s.<ref name="pmid10188789">{{cite journal |vauthors=Adamus WS, Leonard JP, Tröger W | title = Phase I clinical trials with WAL 2014, a new muscarinic agonist for the treatment of Alzheimer's disease | journal = Life Sciences | volume = 56 | issue = 11-12 | pages = 883–90 | year = 1995 | pmid = 10188789 | doi = 10.1016/0024-3205(95)00024-Z| url = }}</ref>

== See also ==
* [[Aceclidine]]
* [[Vedaclidine]]

== References ==
{{Reflist}}

{{Anti-dementia drugs}}
{{Muscarinic acetylcholine receptor modulators}}

[[Category:Muscarinic agonists]]
[[Category:Quinuclidines]]
[[Category:Alkynes]]